Gossamer Bio (GOSS) Interest & Investment Income (2018 - 2026)
Gossamer Bio (GOSS) posted quarterly Interest & Investment Income of -$67000.0 for Q1 2026, down 122.79% year-over-year from $294000.0 in Q1 2025, and down 114.99% quarter-over-quarter from $447000.0 in Q4 2025.
Gossamer Bio (GOSS) Interest & Investment Income (2018 - 2026) Analysis & Trends
Gossamer Bio's Interest & Investment Income history runs 9 years deep, the most recent figure standing at -$67000.0 for Q1 2026.
- In Q1 2026, Interest & Investment Income fell 122.79% year-over-year to -$67000.0; the TTM figure through Mar 2026 stood at $998000.0 (up 161.68% YoY), while the FY2025 annual figure was $2.0 million, up 2113.48% from the prior year.
- Interest & Investment Income for Q1 2026 stood at -$67000.0, down from $447000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $1.9 million in Q4 2022, with the low at -$2.4 million in Q4 2024.
- The 5-year median for Interest & Investment Income is $344000.0 (2024), against an average of $238058.8.
- The sharpest annual moves came in 2022 and 2024: Interest & Investment Income soared 5218.92% in 2022, then plunged 2834.83% in 2024.
- Gossamer Bio's Interest & Investment Income stood at $1.9 million in 2022, then plunged by 95.3% to $89000.0 in 2023, then slumped by 2834.83% to -$2.4 million in 2024, then jumped by 118.36% to $447000.0 in 2025, then tumbled by 114.99% to -$67000.0 in 2026.
- Business Quant data shows GOSS's Interest & Investment Income at -$67000.0 in Q1 2026, $447000.0 in Q4 2025, and $687000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Gossamer Bio | 49.15 Mn | -7.87 Mn | - | 268,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 268,000.00 |
| Mar 31, 2026 | -67,000.00 |
| Dec 31, 2025 | 447,000.00 |
| Sep 30, 2025 | 687,000.00 |
| Jun 30, 2025 | -69,000.00 |
| Mar 31, 2025 | 294,000.00 |
| Dec 31, 2024 | -2.43 Mn |
| Sep 30, 2024 | 547,000.00 |
| Jun 30, 2024 | -25,000.00 |
| Mar 31, 2024 | 344,000.00 |
| Dec 31, 2023 | 89,000.00 |
| Sep 30, 2023 | 405,000.00 |
| Jun 30, 2023 | 695,000.00 |
| Mar 31, 2023 | 587,000.00 |
| Dec 31, 2022 | 1.89 Mn |
| Sep 30, 2022 | 465,000.00 |
| Jun 30, 2022 | -36,000.00 |
| Mar 31, 2022 | 224,000.00 |
| Dec 31, 2021 | -37,000.00 |
| Sep 30, 2021 | 191,000.00 |